Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.
Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.
Deep Genomics develops individualized genetic medicines by creating AI systems that are used to accelerate all steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and trial design.